December 1951 in “Journal of the American Medical Association” Propylthiouracil treatment can cause hair loss.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
March 2025 in “Pediatric Rheumatology” Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
3 citations
,
September 2020 in “Bladder cancer” 5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
47 citations
,
January 2003 in “Current opinion in urology” A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
December 2023 in “Reactions weekly” December 2023 in “Reactions weekly” September 2013 in “Reactions weekly” June 2026 in “British Journal of Dermatology” Ritlecitinib shows promise for treating alopecia areata with significant hair regrowth and no serious side effects.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
5 citations
,
December 2014 in “Medicine and Pharmacy Reports” Ciproterone acetate improves hair regrowth and acne in most female patients.
April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
June 2026 in “British Journal of Dermatology” JAK inhibitors can cause severe acne, limiting their use for hair regrowth.
23 citations
,
April 1999 in “The Journal of Clinical Endocrinology and Metabolism” All treatments reduce hair growth; low dose flutamide most effective with fewer side effects.
October 2019 in “European heart journal” Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.
64 citations
,
March 1984 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Cyproterone acetate effectively reduced hair growth in hirsute patients by lowering androgen levels and altering androgen metabolism.
April 2011 in “Cancer Research” 20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
New steroid derivatives show promise as anticancer agents, even against resistant cells.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
October 2009 in “Reactions Weekly” A woman developed lupus after taking hydroxyurea for two years.
20 citations
,
August 2014 in “Talanta” The method effectively measures drug impact on DHT levels in prostate treatments.
3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
18 citations
,
April 2011 in “Neuropharmacology” 11β-Hydroxylase inhibitors help prevent seizures in mice by boosting natural neurosteroid production.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
6 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.